摘要
目的 探讨抗心律常药物西地兰和艾司洛尔在治疗心房颤动的临床应用价值及安全性。方法 选取2014年8月-2016年8月于本院就诊的117例心房颤动患者的临床资料,根据数字随机分配的原则,将患者分为观察组59例与对照组58例,全部患者均给予治疗原发病,控制临床症状,观察组患者给予吸氧,先后给予速尿、西地兰,之后微量注射泵静脉注射硝酸甘油,5-20μg/min。开始注射硝酸甘油后,建立另一个静脉通道,每30 min给予0.2 mg西地兰,治疗组患者给予静脉注射小剂量艾司洛尔。观察2组患者的临床疗效、治疗后心室率、收缩压、舒张压及不良反应情况。结果 2组患者早期及晚期有效率比较差异无统计学意义。观察发现,治疗后,观察组心室率、收缩压及舒张压改善显著高于对照组患者（P〈0.05）,2组患者不良反应发生率比较,差异具有统计学意义（P〈0.05）。结论 大剂量西地兰联合小剂量艾司洛尔在治疗心房颤动,疗效明显,安全性高,可适当选择应用。
Objective To investigate the clinical value and safety of cedilanid, esmolol in the treatment of atrial fibrillation. Methods From August 2014 to August 2016 our Hospital from 117 patients with atrial fibrillation clinical data, according to the random number distribution principle, the patients were divided into observation group 59 cases and control group of 58 cases, all patients were given the treatment of primary disease, the clinical symptoms, the patients in the observation group were given oxygen, has given furosemide, cedilanid, after micro injection pump intravenous nitroglycerin, 5-20 g/min. Start after the injection of nitroglycerin, establish another vein channel, every 30 min to 0.2 mg patients, the treatment group were treated with intravenous injection of small dose esmolol. The clinical efficacy, ventricular rate, systolic blood pressure, diastolic blood pressure and adverse reactions were observed in two groups. Results The early and late effective rates of the two groups were not significantly different. The observation showed that after treatment, the ventricular rate, systolic pressure and diastolic pressure in the observation group were significantly higher than those in the control group （P〈0.05）, and the incidence of adverse reactions in the two groups was significantly different （P〈0.05）. Conclusion High dose cedilanid combined with small dose esmolol in treatment of atrial fibrillation, obvious curative effect, high safety, can choose the appropriate application.
出处
《中国生化药物杂志》
CAS
2017年第8期278-279,共2页
Chinese Journal of Biochemical Pharmaceutics
